Skip to content

Study · Systematic review · n = 3,447 · 2022

7 results

Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.

Zhong P, Zeng H, Huang M, Fu W, Chen Z

Endocrine4 Jan 2022Cited by 55 (Europe PMC)

PMID34981419 (opens in a new tab)DOI10.1007/s12020-021-02945-1 (opens in a new tab)PepBankPUB-34981419
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, once-weekly semaglutide reduced the percentage change in body weight more than placebo in a meta-analysis of randomized trials.

    In plain wordsIn adults with overweight or obesity, once-weekly semaglutide cut body weight by a larger percentage than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage change in body weight
    Study

    n = 3,447

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Once-weekly semaglutide was superior to placebo in terms of the percentage change and absolute change in body weight.
    2 context sentences
    Summary · context
    We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity.
    Summary · context
    This meta-analysis included a total of four trials with 3447 patients.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, once-weekly semaglutide reduced absolute body weight more than placebo in a meta-analysis of randomized trials.

    In plain wordsIn adults with overweight or obesity, once-weekly semaglutide cut body weight by more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseAbsolute change in body weight
    Study

    n = 3,447

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Once-weekly semaglutide was superior to placebo in terms of the percentage change and absolute change in body weight.
    2 context sentences
    Summary · context
    We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity.
    Summary · context
    This meta-analysis included a total of four trials with 3447 patients.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, once-weekly semaglutide increased the proportions who reached categorical weight reduction targets compared with placebo.

    In plain wordsIn adults with overweight or obesity, more people reached weight loss targets with once-weekly semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseAchievement of categorical weight loss targets
    Study

    n = 3,447

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with placebo, once-weekly semaglutide also led to significant increases in the proportions of achievement of categorical weight reduction targets.
    2 context sentences
    Summary · context
    We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity.
    Summary · context
    This meta-analysis included a total of four trials with 3447 patients.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, once-weekly semaglutide improved other cardiometabolic risk factors more than placebo.

    In plain wordsIn adults with overweight or obesity, once-weekly semaglutide improved other heart and metabolic risk factors more than placebo.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedOther cardiometabolic risk factors
    Study

    n = 3,447

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, the effect on improving other cardiometabolic risk factors and health-related quality of life was more pronounced for once-weekly semaglutide relative to placebo.
    2 context sentences
    Summary · context
    We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity.
    Summary · context
    This meta-analysis included a total of four trials with 3447 patients.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, once-weekly semaglutide improved health-related quality of life more than placebo.

    In plain wordsIn adults with overweight or obesity, once-weekly semaglutide improved quality of life more than placebo.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedHealth-related quality of life
    Study

    n = 3,447

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, the effect on improving other cardiometabolic risk factors and health-related quality of life was more pronounced for once-weekly semaglutide relative to placebo.
    2 context sentences
    Summary · context
    We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity.
    Summary · context
    This meta-analysis included a total of four trials with 3447 patients.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, once-weekly semaglutide reduced waist circumference more than placebo.

    In plain wordsIn adults with overweight or obesity, once-weekly semaglutide cut waist size more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference
    Study

    n = 3,447

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, once-weekly semaglutide induced superior reductions in waist circumference and body-mass index compared with placebo.
    2 context sentences
    Summary · context
    We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity.
    Summary · context
    This meta-analysis included a total of four trials with 3447 patients.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, once-weekly semaglutide reduced body-mass index more than placebo.

    In plain wordsIn adults with overweight or obesity, once-weekly semaglutide lowered body-mass index more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody-mass index
    Study

    n = 3,447

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, once-weekly semaglutide induced superior reductions in waist circumference and body-mass index compared with placebo.
    2 context sentences
    Summary · context
    We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity.
    Summary · context
    This meta-analysis included a total of four trials with 3447 patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.